These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32144996)

  • 1. Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort.
    Kaiyrzhanov R; Zharkinbekova N; Shashkin C; Khaibullin T; Kaishibayeva G; Akhmetzhanov V; Sadykova DZ; Seidinova Z; Taskinbayeva A; Karimova A; Rizig M; Houlden H
    J Parkinsons Dis; 2020; 10(2):707-709. PubMed ID: 32144996
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhaled levodopa (Inbrija) for Parkinson's disease.
    Med Lett Drugs Ther; 2019 May; 61(1572):73-74. PubMed ID: 31169799
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
    Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study.
    Ouma S; Fukae J; Fujioka S; Yamamoto S; Hatano T; Yoritaka A; Okuma Y; Kashihara KI; Hattori N; Tsuboi Y
    Intern Med; 2017; 56(15):1961-1966. PubMed ID: 28768964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy for patients with progressive Parkinson's disease].
    Murata M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1432-7. PubMed ID: 13677891
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
    Mizuno Y; Shimoda S; Origasa H
    J Neural Transm (Vienna); 2018 Jan; 125(1):35-43. PubMed ID: 28091751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa for Parkinson's disease.
    Devos D; Moreau C; Destée A
    N Engl J Med; 2009 Feb; 360(9):935-6; author reply 936. PubMed ID: 19246370
    [No Abstract]   [Full Text] [Related]  

  • 9. Compulsive sexual behaviour in Parkinson's disease is associated with higher doses of levodopa.
    Barbosa PM; Grippe T; Lees AJ; O'Sullivan S; Djamshidian A; Warner TT
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1121-1123. PubMed ID: 29175897
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there addiction to levodopa in patients with Parkinson's disease?
    Merims D; Galili-Mosberg R; Melamed E
    Mov Disord; 2000 Sep; 15(5):1014-6. PubMed ID: 11009217
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 12. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Kimber TE; Schoeman M
    Parkinsonism Relat Disord; 2014 Jul; 20(7):786-8. PubMed ID: 24721490
    [No Abstract]   [Full Text] [Related]  

  • 14. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world pharmacological treatment patterns of patients with young-onset Parkinson's disease in Japan: a medical claims database analysis.
    Kasamo S; Takeuchi M; Ikuno M; Kawasaki Y; Tanaka S; Takahashi R; Kawakami K
    J Neurol; 2019 Aug; 266(8):1944-1952. PubMed ID: 31076875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion.
    Santos-García D; Macías M; Llaneza M; Grande M; de la Fuente-Fernández R
    Mov Disord; 2011 Feb; 26(3):558-9. PubMed ID: 20960480
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
    Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T
    Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    Olanow CW; Stocchi F
    Eur J Neurol; 2000 May; 7 Suppl 1():3-8. PubMed ID: 11054152
    [No Abstract]   [Full Text] [Related]  

  • 20. [Duodenal levodopa infusion for advanced Parkinson's disease in Finland 2006-2010].
    Pursiainen V; Pekkonen E
    Duodecim; 2012; 128(16):1707-15. PubMed ID: 23025155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.